Form 4 for CYTK CYTOKINETICS INC
Accepted 2026-04-08 16:18:55 ET · period of report 2026-04-07 · accession 0001061983-26-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-08 16:18 | 2026-04-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $8.42 | +4,500 | 154.9K | +3% | +$37.9K |
| DMT | 2026-04-08 16:18 | 2026-04-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $65.11 | -4,500 | 153.9K | -3% | -$293.0K |
| DMT | 2026-04-08 16:18 | 2026-04-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -4,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-07 | M | A | 3,500 | $7.80 | 157,402 | D | — | — | |
| 2 | Common | Common Stock | 2026-04-07 | S | D | 3,500 | $65.21 | 153,902 | D | — | — | |
| 3 | Common | Common Stock | 2026-04-07 | M | A | 1,000 | $10.60 | 154,902 | D | — | — | |
| 4 | Common | Common Stock | 2026-04-07 | S | D | 1,000 | $64.75 | 153,902 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2026-04-07 | M | D | 3,500 | $0.00 | 58,386 | D | $7.80 · 2018-03-27 to 2028-02-27 | 3,500 Common Stock | |
| 6 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2026-04-07 | M | D | 1,000 | $0.00 | 0 | D | $10.60 · 2017-03-28 to 2027-02-28 | 1,000 Common Stock |